Sorafenib activates Akt [8] and its downstream factors such as ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) in HCC cells [9, 10]. Here, AKT1 is linked to hepatocellular carcinoma.